
Quarterly report 2025-Q3
added 11-13-2025
Neoleukin Therapeutics Financial Ratios 2011-2025 | NLTX
Annual Financial Ratios Neoleukin Therapeutics
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
P/E |
0.1 | -0.7 | -2.3 | -20.5 | -4.6 | -1.7 | -6.1 | -9.0 | -6.1 | -3.8 | - | - | - |
P/S |
- | - | - | - | - | 2.1 | - | - | - | - | - | - | - |
EPS |
27.8 | -1.0 | -1.1 | -0.6 | -2.6 | -1.3 | -2.1 | -2.0 | -1.7 | -2.8 | -49.5 | -40.2 | - |
EV (Enterprise Value) |
-110 M | -33.8 M | 19.9 M | 509 M | 180 M | -19.3 M | 264 M | 311 M | 98 M | 82.3 M | -6.12 M | 51.4 M | - |
EBITDA per Share |
-106 | -0.97 | -1.08 | -0.879 | -0.847 | -1.34 | -2.14 | -1.96 | -1.72 | -2.57 | - | - | - |
EV/EBITDA |
0.2 | -10.3 | -7.6 | 0.8 | -5.0 | -8.1 | -4.3 | -3.5 | - | - | - | ||
PEG |
0.0 | 0.06 | 0.3 | -0.27 | 0.05 | -0.04 | 0.66 | 0.68 | -0.16 | 0.05 | - | - | - |
P/B |
0.0 | 0.4 | 1.0 | 3.6 | 2.2 | 0.7 | 3.1 | 2.3 | 1.2 | 2.5 | - | - | - |
P/CF |
-0.0 | -0.7 | -3.0 | -25.5 | -19.5 | -1.7 | -6.7 | -10.8 | -6.5 | -5.1 | - | - | - |
ROE % |
7.34 | 37.87 | -42.48 | -17.40 | -49.01 | -43.46 | -50.75 | -25.58 | -20.16 | -66.47 | - | - | - |
ROA % |
6.13 | -50.51 | -37.17 | -15.81 | -47.23 | -40.69 | -45.48 | -23.97 | -19.29 | -58.00 | - | - | - |
ROCE % |
-29.88 | 38.78 | -42.49 | -20.51 | -16.34 | -44.70 | -51.44 | -25.99 | -19.66 | -61.78 | - | - | - |
Current Ratio |
6.1 | 10.3 | 8.0 | 24.7 | 30.3 | 16.7 | 9.9 | 10.9 | 15.6 | 7.6 | - | - | - |
DSO |
- | - | - | - | - | 3.5 | - | - | - | - | - | - | - |
All numbers in USD currency
Quarterly Financial Ratios Neoleukin Therapeutics
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
EPS |
-0.99 | -1.05 | -1.08 | - | -1.19 | -1.09 | -1 | - | -32.67 | -26.68 | -0.26 | - | -1.18 | -0.28 | -0.28 | - | -0.28 | -0.27 | -0.27 | - | -0.04 | -0.2 | -0.18 | - | -2.26 | -0.09 | -0.09 | - | -0.64 | 0.12 | -0.62 | - | -0.5 | -0.59 | -0.36 | - | -0.46 | -0.63 | -0.39 | - | -0.43 | -0.44 | -0.6 | - | -0.59 | -0.51 | -1.28 | - | -15.64 | -7.89 | -8.48 | - | - | - | - | - | - | - | - |
EBITDA per Share |
-1.09 | -1.2 | -1.2 | - | -1.26 | -1.14 | -1.06 | - | -32.3 | -26.5 | -0.27 | - | -1.12 | -0.27 | -0.27 | - | -0.26 | -0.26 | -0.27 | - | -0.03 | -0.19 | -0.18 | - | -2.27 | -0.01 | - | - | -0.65 | 0.11 | - | - | -0.51 | -0.6 | - | - | - | - | - | - | - | - | - | - | - | 0.01 | 0.01 | - | 0.15 | 0.05 | 0.05 | - | - | - | - | - | - | - | - |
ROE % |
-38.42 | -45.24 | -49.12 | -36.55 | -28.59 | -5.92 | 13.02 | -2.49 | -14.86 | -35.19 | -55.65 | -37.62 | -47.59 | -45.19 | -40.80 | -27.38 | -28.56 | -19.76 | -15.80 | -10.79 | -52.53 | -93.08 | -87.99 | -43.29 | -63.92 | -42.82 | -38.81 | -36.74 | -48.70 | -40.04 | -57.98 | -34.30 | -39.93 | -33.59 | -27.21 | -17.81 | -22.45 | -21.46 | -18.31 | -14.94 | -32.32 | -45.06 | -55.69 | -44.09 | -38.96 | -16.45 | -0.21 | 7.90 | 7.90 | 2.77 | 1.54 | - | - | - | - | - | - | - | - |
ROA % |
-34.19 | -39.22 | -42.10 | -22.60 | -38.87 | -42.83 | -45.16 | -43.31 | -53.64 | -47.70 | -46.53 | -32.07 | -40.85 | -39.30 | -35.94 | -24.34 | -25.41 | -17.70 | -14.24 | -9.80 | -50.02 | -89.17 | -84.54 | -41.72 | -61.04 | -40.14 | -36.38 | -34.40 | -45.12 | -36.53 | -52.77 | -30.74 | -36.02 | -30.57 | -25.15 | -16.68 | -21.13 | -20.29 | -17.42 | -14.29 | -29.46 | -40.19 | -49.09 | -38.47 | -59.99 | -66.34 | -58.43 | -33.16 | -33.16 | -11.64 | -6.46 | - | - | - | - | - | - | - | - |
ROCE % |
-43.53 | -50.71 | -54.15 | -40.13 | -31.82 | -7.37 | 13.07 | -2.85 | -15.73 | -36.92 | -57.97 | -38.29 | -48.27 | -45.36 | -40.82 | -27.38 | -28.56 | -19.76 | -15.81 | -11.03 | -53.03 | -93.86 | -89.06 | -42.31 | -63.22 | -42.13 | -38.12 | -17.21 | -29.42 | -20.71 | -38.56 | -26.36 | -26.36 | -14.15 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Current Ratio |
12.9 | 12.4 | 13.4 | 13.2 | 6.2 | 7.2 | - | 6.1 | 6.2 | 6.5 | 5.8 | 5.4 | 6.0 | 6.8 | 7.8 | 8.0 | 8.3 | 9.4 | 9.5 | 10.9 | 10.9 | 10.9 | 10.9 | 27.6 | 27.6 | 27.6 | 27.6 | 15.7 | 15.7 | 15.7 | 15.7 | 9.6 | 9.6 | 9.6 | 9.6 | 15.9 | 15.9 | 15.9 | 15.9 | 23.0 | 23.0 | 23.0 | 23.0 | 7.8 | 7.8 | 7.8 | 7.8 | 2.1 | 2.1 | 2.1 | 2.1 | - | - | - | - | - | - | - | - |
All numbers in USD currency
Multiples are an important financial analysis tool for the company Neoleukin Therapeutics, allowing investors and analysts to quickly assess the company’s value and investment attractiveness based on the ratio of market indicators to the company’s financial performance. Essentially, multiples express how the market values the company relative to its earnings, revenue, equity, or other key metrics.
Advantages of Using Financial Ratios- Simplified Data Analysis
Financial ratios transform large volumes of accounting data into compact and easily interpretable indicators, significantly simplifying the assessment of the company’s condition. - Comparability Between Companies
Multiples standardize financial metrics, enabling objective comparison of companies of different sizes, industries, and market capitalizations. - Identification of Trends and Issues
Regular analysis of ratios helps track the dynamics of financial health, identify strengths and weaknesses of the business, as well as potential risks. - Decision Support
Financial multiples serve as an important tool for investors, creditors, and company management in making investment, credit, and managerial decisions. - Accelerated Assessment of Investment Attractiveness
Ratios allow quick determination of key performance, liquidity, and financial stability indicators, facilitating prompt evaluation of companies’ attractiveness for investments.
Using multiples enables comparison between companies, even if they differ in size or industry, as they standardize financial data into ratios convenient for analysis. This is especially useful for evaluating companies where direct analysis of financial statements may be complex or require in-depth knowledge.
Financial Ratios of other stocks in the Drug manufacturers industry
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
|
Alimera Sciences
ALIM
|
- | - | $ 142 M | ||
|
Canopy Growth Corporation
CGC
|
$ 1.7 | 50.0 % | $ 183 M | ||
|
Cronos Group
CRON
|
$ 3.24 | 13.51 % | $ 1.69 B | ||
|
DURECT Corporation
DRRX
|
- | - | $ 50.1 M | ||
|
Endo International plc
ENDP
|
- | - | $ 28.9 M | ||
|
AcelRx Pharmaceuticals
ACRX
|
- | 7.5 % | $ 6.35 M | ||
|
Adamis Pharmaceuticals Corporation
ADMP
|
- | 0.86 % | $ 117 M | ||
|
Aerie Pharmaceuticals
AERI
|
- | - | $ 754 M | ||
|
Agile Therapeutics
AGRX
|
- | 10.11 % | $ 58.2 M | ||
|
Harrow Health
HROW
|
$ 47.18 | -7.67 % | $ 1.54 B | ||
|
Aurora Cannabis
ACB
|
$ 5.36 | 17.8 % | $ 86.3 M | ||
|
Catalent
CTLT
|
- | - | $ 11.5 B | ||
|
Calliditas Therapeutics AB (publ)
CALT
|
- | -0.1 % | $ 2.03 B | ||
|
HEXO Corp.
HEXO
|
- | 2.45 % | $ 38.1 M | ||
|
Eagle Pharmaceuticals
EGRX
|
- | -39.89 % | $ 27.7 M | ||
|
Emergent BioSolutions
EBS
|
$ 11.46 | -2.22 % | $ 587 M | ||
|
Evoke Pharma
EVOK
|
$ 10.97 | 0.18 % | $ 36.7 M | ||
|
Athenex
ATNX
|
- | -23.39 % | $ 1.76 M | ||
|
Avadel Pharmaceuticals plc
AVDL
|
$ 21.38 | -0.05 % | $ 2.03 B | ||
|
Pacira BioSciences
PCRX
|
$ 26.28 | 2.14 % | $ 1.22 B | ||
|
Evolus
EOLS
|
$ 6.99 | 1.09 % | $ 433 M | ||
|
PetIQ
PETQ
|
- | 1.64 % | $ 400 M | ||
|
China Pharma Holdings
CPHI
|
$ 1.67 | 11.33 % | $ 29.2 M | ||
|
Perrigo Company plc
PRGO
|
$ 13.13 | -2.23 % | $ 1.8 B | ||
|
ProPhase Labs
PRPH
|
$ 0.12 | -15.26 % | $ 1.9 M | ||
|
Rockwell Medical
RMTI
|
$ 0.93 | -2.37 % | $ 21.7 M | ||
|
Recro Pharma
REPH
|
- | -4.76 % | $ 65.3 M | ||
|
Bausch Health Companies
BHC
|
$ 6.95 | -0.93 % | $ 2.54 B | ||
|
SCYNEXIS
SCYX
|
$ 0.64 | -0.02 % | $ 30.6 M | ||
|
Assertio Holdings
ASRT
|
$ 0.77 | -1.79 % | $ 54.7 M | ||
|
OrganiGram Holdings
OGI
|
$ 1.88 | 14.72 % | $ 402 M | ||
|
Solid Biosciences
SLDB
|
$ 5.85 | -0.34 % | $ 239 M | ||
|
Lannett Company
LCI
|
- | 1.15 % | $ 7.11 M | ||
|
Organogenesis Holdings
ORGO
|
$ 4.83 | 1.15 % | $ 636 M | ||
|
Sonoma Pharmaceuticals
SNOA
|
$ 3.59 | -3.37 % | $ 4.46 M | ||
|
Cumberland Pharmaceuticals
CPIX
|
$ 2.61 | 4.99 % | $ 36.7 M | ||
|
Relmada Therapeutics
RLMD
|
$ 4.12 | -1.67 % | $ 124 M | ||
|
Jupiter Wellness
JUPW
|
- | - | $ 33.6 M | ||
|
Radius Health
RDUS
|
- | - | $ 1.42 B | ||
|
Sundial Growers
SNDL
|
$ 2.19 | 24.01 % | $ 3.37 M | ||
|
OptiNose
OPTN
|
- | - | $ 1.08 B | ||
|
Veru
VERU
|
$ 2.45 | -4.3 % | $ 330 M | ||
|
PLx Pharma
PLXP
|
- | -27.8 % | $ 2.56 M | ||
|
cbdMD
YCBD
|
$ 1.18 | 87.31 % | $ 5.09 M | ||
|
Zomedica Corp.
ZOM
|
- | -0.21 % | $ 98 M | ||
|
Tricida
TCDA
|
- | - | $ 3.25 M | ||
|
Tilray
TLRY
|
$ 11.86 | 40.68 % | $ 7.33 B | ||
|
Zynerba Pharmaceuticals
ZYNE
|
- | - | $ 55.5 M | ||
|
TherapeuticsMD
TXMD
|
$ 1.79 | -2.72 % | $ 18.7 M |